ImmunoPrecise Antibodies is a Canada‐based biotechnology company specializing in the discovery and development of custom antibodies for research, diagnostic, and therapeutic applications. Operating as a contract research organization (CRO), the company applies an array of proprietary platforms—ranging from hybridoma and phage display to single B‐cell cloning—to generate monoclonal, polyclonal, and recombinant antibodies tailored to client specifications. By integrating advanced immunization protocols with high‐throughput screening and deep sequencing, ImmunoPrecise supports early‐stage target validation and lead candidate selection across a broad spectrum of disease areas.
The company’s service portfolio extends from antigen design and immunization strategy through antibody humanization, affinity maturation, and scalable cell‐line development. In addition to discovery services, ImmunoPrecise offers comprehensive analytical testing and characterization, including epitope mapping, cross‐reactivity profiling, and in vitro potency assays. These capabilities are complemented by process development expertise aimed at streamlining downstream manufacturing and regulatory support, enabling clients to transition smoothly from preclinical research to clinical development.
Founded in 2006 and headquartered in Victoria, British Columbia, ImmunoPrecise has expanded its global footprint with laboratories and offices in North America, Europe, and Asia–Pacific. This geographic diversity allows the company to serve pharmaceutical, biotechnology, and diagnostic firms worldwide, including those focused on oncology, infectious disease, neuroscience, and autoimmune disorders. Through strategic collaborations and targeted acquisitions, ImmunoPrecise continues to broaden its technological offerings and enhance its capacity to accelerate antibody programs on a global scale.
ImmunoPrecise is led by an experienced management team with extensive backgrounds in biopharmaceutical R&D, corporate development, and operations. The company’s leadership emphasizes a client‐centric approach and invests in continuous innovation to maintain a competitive edge in antibody engineering. With a track record of delivering over a thousand custom antibody projects, ImmunoPrecise Antibodies positions itself as a trusted partner for organizations seeking to translate novel biology into targeted antibody therapies and diagnostics.
AI Generated. May Contain Errors.
Free IPATF Stock Alerts